Bayer Wins FDA Fast-Track for Lynkuet as JPMorgan Flags Stretched Q3 Hopes

FDA accepts supplemental filing for Lynkuet in breast cancer treatment-related hot flushes; Bayer sells Stivarga rights to Grünenthal for up to EUR 375 million.

US regulators have agreed to expedite their review of one of Bayer's most closely watched pipeline candidates. The FDA accepted a supplemental application for Lynkuet, whose active ingredient is elinzanetant, and handed the filing Priority Review status — a designation that typically shortens the approval timeline well below the standard track.

The submission covers the drug's use in treating moderate-to-severe vasomotor symptoms in women undergoing endocrine therapy for hormone receptor-positive breast cancer. For the Leverkusen-based group, the regulatory nod marks a milestone in widening Lynkuet's therapeutic reach, targeting patients who endure severe hot flushes and similar complaints as a consequence of their cancer treatment.

Portfolio Housekeeping Runs Alongside Pipeline Push

While pushing its internal development programs forward, Bayer is simultaneously shedding older products. Fellow German pharma company Grünenthal has struck a deal to acquire the rights to the cancer drug Stivarga, in a transaction worth up to EUR 375 million. Completion hinges on customary conditions and antitrust clearances, with both sides expecting the deal to close around the end of 2026 or early 2027.

The divestment slots into a broader reshaping of Bayer's pharmaceutical operations. On the manufacturing side, the company is planning long-term capacity expansions, including a production site in the US state of Ohio carrying an estimated price tag of USD 2.2 billion. That facility is slated to create roughly 600 jobs, with the first production module targeted to come online in 2031. To help fund these activities, Bayer placed hybrid bonds totaling EUR 2 billion on the capital market in September. In a related personnel move, Dr. Christoph Koenen stepped into the role of Chief Medical Officer for the pharma division.

Legal Clouds Keep Investors on Edge

Operational ambitions aside, litigation remains the dominant source of uncertainty for shareholders. According to media reports, the legal disputes weigh heavily on the stock. In Missouri, another Roundup trial got underway, with three female plaintiffs accusing the company of inadequate testing of the herbicide. The case sits outside the proposed global settlement and is proceeding despite a US Supreme Court ruling on warning labels. Bayer has rejected the allegations. Adding to the pressure, a court roughly a week earlier declined to dismiss patent lawsuits tied to mRNA technology.

Those legal overhangs are complicating the group's efforts to press ahead with its strategic overhaul, and for investors the unanswered question of what the US cases will ultimately cost remains the single biggest unknown.

Analyst Caution Ahead of the Q3 Print

Sentiment in the market was already fragile. Bayer shares finished Friday's session at EUR 45.02, leaving the stock down 10% over the week — though it is still up 22% since the start of the year.

Ahead of the upcoming results, JPMorgan's Richard Vosser kept his "Overweight" rating and a EUR 61 price target intact, but cautioned that early consensus estimates for the third quarter look too optimistic. His chief explanation: timing shifts in the agricultural business. The analyst expects full-year forecasts to be largely unaffected by the discrepancy.

Concrete clarity on the operating picture will arrive on November 3, 2026, when Bayer publishes its official quarterly report for the third fiscal quarter. Only those hard numbers will show whether the cautious stance taken by analysts was warranted.